Literature DB >> 16925081

Conus medullaris schistosomiasis.

Feng Wan1, Ling Li, Jingcao Chen, Jian Chen, Ting Lei, Delin Xue, Hongquan Niu, Kai Shu, Ping Zhang, Zhengming Yang, Yuping Wang.   

Abstract

OBJECT: The authors performed a study to investigate the clinical manifestations, treatment strategies, and possible pathogenesis of conus medullaris schistosomiasis.
METHODS: Six cases collected from the authors' experience and four cases reported in the literature were studied retrospectively for clinical manifestations, treatment outcomes, and prognosis. All patients experienced progressive lower-extremity weakness and functional bowel and bladder impairment. Although the magnetic resonance (MR) imaging results suggested the presence of a conus medullaris tumor, schistosomiasis was diagnosed based on pathological results obtained in the 10 patients. The results of surgery followed by pyquiton and hormone treatment confirmed the diagnosis, and the patients' prognoses were good.
CONCLUSIONS: This pathological entity is predominantly found in adults, and the clinical manifestations have no specificity, although the MR imaging may provide some clues. As a form of ectopic schistosomiasis, conus medullaris schistosomiasis deserves special consideration and further exploration. If an early diagnosis can be made and pyquiton and hormone therapy is given, surgery can be avoided and the prognosis will remain good.

Entities:  

Mesh:

Year:  2006        PMID: 16925081     DOI: 10.3171/spi.2006.5.2.146

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  2 in total

1.  Myeloradiculopathy associated to Schistosoma mansoni.

Authors:  Patrícia Pita Lobo; Miguel Coelho; Ruth Geraldes; Carolina Santos; Maria Grácio; Mário Miguel Rosa; João Lobo Antunes
Journal:  BMJ Case Rep       Date:  2011-08-11

Review 2.  Intramedullary lesions of the conus medullaris: differential diagnosis and surgical management.

Authors:  Florian H Ebner; Florian Roser; Marcus A Acioly; Wolfgang Schoeber; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2008-09-27       Impact factor: 3.042

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.